{'fraction_non_alphanumeric': 0.03004694835680751, 'fraction_numerical': 0.0018779342723004694, 'mean_word_length': 5.460606060606061, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
More novel diagnostic antibodies for celiac disease

The updated review entitled: ‘Novel diagnostic techniques for celiac disease’ published by the Finnish celiac disease (CD) experts [1] encompasses the most recent techniques to diagnose the disease and hopefully will encourage the professional communities to search for this vastly underdiagnosed condition. In the section on new serological tests, the most frequently used test and that recommended by the CD societies, the anti-TG2 autoantibody is mentioned, as is the anti-deamidated gliadin peptide test. It is appropriate to mention that there is an additional new serological biomarker for CD on the market. The tTg neo-epitope (tTg-neo) results from tTg complexing to gliadin due to the enzyme–substrate interaction. This cross-linking induces chemical, physical, and three-dimensional configured modifications that unravel or create neo-epitopes on the complex to which antibodies that bind to the tTg neo-epitope complex have been defined. Several aspects, concerning tTg-neo, are worthwhile mentioning: